Nurix Therapeutics Down 7.4% After Wider 2025 Losses and New ESOP Share Shelf Registration

Nurix Therapeutics reported FY25 revenue of $83.98 million and a net loss of $264.46 million, with a Q4 loss of $78.22 million. The company filed a $98.80 million shelf registration for 5.09 million shares of common stock tied to an ESOP-related offering. Despite revenue growth, widening losses and ongoing equity issuance are concerns for investors. The company's share price may be too optimistic, and investors should be aware of the potential risks.